What is Processa Pharmaceuticals Inc (PCSA) stock price today?

Processa Pharmaceuticals Inc (PCSA) currently trades at $2.70 per share. The stock has a market capitalization of $7.93M and a P/E ratio of —x.

Is PCSA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Processa Pharmaceuticals Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -51.32.

Is Processa Pharmaceuticals Inc financially healthy?

Processa Pharmaceuticals Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -51.32 places it in the distress.

PCSA

Processa Pharmaceuticals Inc

NASDAQ: PCSA · HEALTHCARE · BIOTECHNOLOGY

$2.70

+1.89% today

Updated 2026-04-30

Market cap

$7.93M

P/E ratio

—

P/S ratio

1,320.06x

EPS (TTM)

$-10.36

Dividend yield

—

52W range

$2 – $20

Volume

0.1M

Market cap

$7.93M

P/E ratio

—

P/S ratio

1,320.06x

EPS (TTM)

$-10.36

Dividend yield

—

52W range

$2 – $20

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.8

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-51.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$25.00

+825.93%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -51.32 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-2.90M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-27.42M	$-11.12M	$-11.85M	$-13.56M	$-3.36M
EPS	—	—	—	—	$-10.36
Free cash flow	$-9.61M	$-8.07M	$-11.25M	$-11.39M	$-2.90M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PCSA	$7.93M	23	4.3	3.0	5.0	4.8	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Processa Pharmaceuticals Inc trades at $2.70. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -51.32, it sits in the distress.

Frequently asked questions

What is Processa Pharmaceuticals Inc's stock price?

Processa Pharmaceuticals Inc (PCSA) trades at $2.70.

Is Processa Pharmaceuticals Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Processa Pharmaceuticals Inc (PCSA)?

The analyst target price is $25.00, representing +825.9% upside from the current price of $2.70.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-51.32 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.processapharmaceuticals.com

Quick metrics

P/S ratio1,320.06x

ROE-373.00%

Beta0.89

50D MA$2.63

200D MA$4.85

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PCSA vs LLY →PCSA vs JNJ →PCSA vs ABBV →Stock screener →